Conception and design: Tatsuo Akechi, Takuhiro Yamaguchi, Fuminobu Imai, Kanae Momino, Fujika Katsuki, Naomi Sakurai, Tempei Miyaji, Toshi A. Furukawa, Yosuke Uchitomi, Hiroji Iwata

Financial support: Tatsuo Akechi

Administrative support: Tatsuo Akechi, Megumi Uchida, Fujika Katsuki, Shinji Ohno, Kenji Higaki, Yosuke Uchitomi

Provision of study materials or patients: Tatsuo Akechi, Naomi Sakurai, Masaru Horikoshi, Toshi A. Furukawa, Akiyo Yoshimura, Shinji Ohno, Natsue Uehiro, Kenji Higaki, Yoshie Hasegawa, Kazuhisa Akahane, Hiroji Iwata

Collection and assembly of data: Tatsuo Akechi, Naomi Sakurai, Tempei Miyaji, Tomoe Mashiko, Akiyo Yoshimura, Shinji Ohno, Natsue Uehiro, Kenji Higaki, Yoshie Hasegawa, Kazuhisa Akahane, Hiroji Iwata

Data analysis and interpretation: Tatsuo Akechi, Takuhiro Yamaguchi, Megumi Uchida, Fuminobu Imai, Tempei Miyaji, Tomoe Mashiko, Masaru Horikoshi, Toshi A. Furukawa, Yosuke Uchitomi, Hiroji Iwata

Manuscript writing: All authors

Final approval of manuscript: All authors

Accountable for all aspects of the work: All authors

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Smartphone Psychotherapy Reduces Fear of Cancer Recurrence Among Breast Cancer Survivors: a Fully Decentralized Randomized Controlled Clinical Trial (J-SUPPORT 1703 Study)

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Tatsuo Akechi

Honoraria: lectures fees from Chugai, Daiichi-Sankyo, Dainippon-Sumitomo, Eizai, Janssen, Kyowa, Lilly, MSD, Meiji-Seika Pharma, Mochida, Otsuka, Takeda, and Viatris, and royalties from Igaku-Shoin

Patents, Royalties, Other Intellectual Property: The inventor of the pending patents (2020-135195) (Inst)

Takuhiro Yamaguchi

Stock and Other Ownership Interests: STATCOM

Consulting or Advisory Role: Ono Pharmaceutical, Kowa, Japan Tobacco Inc, Chugai Pharma, DAIICHI SANKYO COMPANY, LIMITED, Eisai, EP Croit Co., Ltd, 3H Clinical Trial, SONIRE Therapeutics Inc, SEIKAGAKU CORPORATION, Otsuka, Incyte

Speakers' Bureau: Daiichi Sankyo, Takeda, Mebix, AstraZeneca

Research Funding: AC Medical (Inst), A2 Healthcare (Inst), Facet Biotech (Inst), Japan Tobacco Inc (Inst), Japan Media Corporation (Inst), Medidata Solutions, Inc (Inst), Ono Pharmaceutical (Inst), intellim (Inst), Welby (Inst), 3H Medi Solution (Inst), NIPRO CORPORATION (Inst), Hemp Kitchen (Inst), Nobori Ltd (Inst), Puravida Technologies (Inst), Medrio (Inst), 3H Clinical Trial (Inst), Senju Pharmaceutical (Inst), Otsuka (Inst), Eisai (Inst), ClinChoice (Inst), Kyowa Kirin Co., Ltd

Tempei Miyaji

Honoraria: Pfizer, Takeda, Merck, AYUMI, Welby

Research Funding: AC Medical (Inst), A2 Healthcare (Inst), CAC Croit Corporation (Inst), Japan Tobacco Inc (Inst), Japan Media Corporation (Inst), Luminary Medical (Inst), Medidata Solutions, Inc (Inst), Ono Pharmaceutical (Inst), FMD K&L Japan (Inst), intellim (Inst), Welby (Inst), 3H Medi Solution (Inst), Nipro Corporation (Inst), New Age Trading (Inst), NOBORI Ltd (Inst), Puravida Technologies (Inst), Medrio (Inst)

Toshi A. Furukawa

Honoraria: Mitsubishi Tanabe Pharma, SONY, Kyoto University Original, Shionogi

Research Funding: Mitsubishi Tanabe Pharma (Inst), Shionogi (Inst)

Patents, Royalties, Other Intellectual Property: Patent 2018-177688 pending (Inst), Patent 2022-082495 pending (Inst), Intellectual properties for Kokoro-app (Inst)

Akiyo Yoshimura

Honoraria: Chugai Pharma, AstraZeneca, Lilly, Pfizer, ACTmed

Shinji Ohno

Speakers' Bureau: Chugai/Roche, Lilly Japan, AstraZeneca, AstraZeneca, Eisai, Kyowa Kirin International, Lilly Japan, Nihonkayaku, Pfizer, Daiichi Sankyo/UCB Japan, Taiho Pharmaceutical, MSD

Research Funding: Taiho Pharmaceutical (Inst), Taiho Pharmaceutical (Inst), Eisai (Inst), Eisai (Inst)

Hiroji Iwata

Honoraria: Chugai Pharma, AstraZeneca, Eisai, Pfizer, Daiichi Sankyo, Lilly Japan, Kyowa Hakko Kirin, Taiho Pharmaceutical, MSD

Consulting or Advisory Role: Chugai Pharma, Daiichi Sankyo, Pfizer, AstraZeneca, Lilly Japan, Kyowa Hakko Kirin, Novartis, MSD, Sanofi

Research Funding: MSD (Inst), AstraZeneca (Inst), Kyowa Hakko Kirin (Inst), Daiichi Sankyo (Inst), Chugai Pharma (Inst), Nihonkayaku (Inst), Lilly Japan (Inst), Novartis (Inst), Bayer (Inst), Pfizer (Inst), Boehringer Ingelheim (Inst), Sanofi (Inst), Amgen (Inst)

No other potential conflicts of interest were reported.